Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytek Biosciences (CTKB) Non Operating Income (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Non Operating Income for 6 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Income rose 166.16% year-over-year to $2.0 million, compared with a TTM value of $10.5 million through Dec 2025, up 136.18%, and an annual FY2025 reading of $10.5 million, up 136.23% over the prior year.
  • Non Operating Income was $2.0 million for Q4 2025 at Cytek Biosciences, up from $1.3 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $4.4 million in Q3 2024 and bottomed at -$3.0 million in Q4 2024.
  • Average Non Operating Income over 5 years is $1.2 million, with a median of $1.3 million recorded in 2024.
  • The sharpest move saw Non Operating Income tumbled 541.94% in 2021, then soared 596.47% in 2023.
  • Year by year, Non Operating Income stood at $819000.0 in 2021, then surged by 405.13% to $4.1 million in 2022, then dropped by 22.79% to $3.2 million in 2023, then crashed by 194.65% to -$3.0 million in 2024, then surged by 166.16% to $2.0 million in 2025.
  • Business Quant data shows Non Operating Income for CTKB at $2.0 million in Q4 2025, $1.3 million in Q3 2025, and $3.5 million in Q2 2025.